Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Tag: biomarkers

  • What Does the Published Research Say About CJC-1295 Without DAC?

    Research Context

    This synthesis isolates what the included literature shows—and does not show—about CJC-1295 without DAC. The packet contains: two human study sources (a pharmacodynamic study in healthy adults and a human biomarker study; plus a clinical trial registry entry in a disease-specific context), one netnographic review source, and three preclinical/analytical sources. Importantly, the direct human data provided (e.g., [pubmed:16352683], [pubmed:19386527]) describe a long-acting CJC-1295 GHRH analog; these should not be treated as interchangeable with a non-DAC variant.

    Key Takeaway

    Most direct human findings in this packet concern a long-acting CJC-1295 formulation, not a non-DAC variant. Evidence shows GH/IGF-1 biomarker changes and lists a disease-specific trial, but no human outcome data specific to a non-DAC variant are included.

    Direct Answer

    Published research in this packet shows that a long-acting CJC-1295 GHRH analog can prolong GH and IGF-1 secretion in healthy adults and alter serum protein profiles (biomarker-level findings) [pubmed:16352683][pubmed:19386527]. A clinical trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, but no peer-reviewed outcomes are provided here [clinicaltrials:NCT00267527]. Netnographic review literature documents non-medical use narratives [pubmed:26771670]. Analytical studies in equine matrices describe detection methods, not therapeutic effects [pubmed:30938069][pubmed:30489688]. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant.

    —

    Direct Human Evidence

    • Pharmacodynamic study (healthy adults): A long-acting CJC-1295 GHRH analog produced prolonged stimulation of GH and IGF-1 secretion. Context noted that native GHRH has short duration, motivating evaluation of longer-acting analogs [pubmed:16352683].
    • Human biomarker/mechanistic study (normal adults): Activation of the GH/IGF-1 axis by CJC-1295 (long-acting GHRH analog) was associated with changes in serum protein profiles. This is biomarker-level/mechanistic evidence and not controlled clinical outcome data [pubmed:19386527].
    • Disease-specific clinical trial registry entry: A study was registered to evaluate CJC-1295 in HIV patients with visceral obesity; the packet does not provide peer-reviewed outcomes from this trial [clinicaltrials:NCT00267527].

    Variant alignment clarification: The human studies above pertain to a long-acting CJC-1295 formulation. Given this article’s focus on “CJC-1295 without DAC,” these data should not be used as stand-in evidence for a non-DAC variant.

    —

    Review and Observational Context

    • Netnography of female use narratives: Documents online “folk pharmacology” describing interests such as muscle enhancement, fat loss, and skin appearance related to CJC-1295. This frames context but does not constitute primary human outcome evidence [pubmed:26771670].

    —

    Preclinical, Mechanistic, and Analytical Evidence

    • Analytical method development (equine plasma):
    • LC–MS/MS method to confirm CJC-1295 in equine plasma [pubmed:30938069].
    • Immuno-PCR screening for GHRH analogs in equine plasma [pubmed:30489688].

    These are analytical/anti-doping methods, not therapeutic or outcome studies.

    • Human biomarker/mechanistic example (for clarity, still human, not outcomes): Serum protein profile changes consistent with GH/IGF-1 axis activation following exposure to a long-acting GHRH analog [pubmed:19386527]. This informs mechanism/biomarkers but not clinical efficacy.

    These findings should not be presented as established human therapeutic outcomes.

    —

    What Is Not Established

    • No direct human outcome data specific to a non-DAC CJC-1295 variant are included in this packet.
    • Dosing and general safety across off-label or non-study populations are not addressed here.
    • Biomarker changes (GH/IGF-1, serum protein profiles) do not establish clinical benefit [pubmed:16352683][pubmed:19386527].
    • Extrapolation from a disease-specific registry entry (HIV-associated visceral obesity) to broader populations or indications is not supported without published outcomes [clinicaltrials:NCT00267527].
    • Analytical method papers in equine models are not evidence of therapeutic effects [pubmed:30938069][pubmed:30489688].

    —

    Conclusion

    Within this packet, human evidence centers on long-acting CJC-1295 analogs that modulate GH/IGF-1 and associated biomarkers, plus a trial registered in a specific disease context without outcomes provided. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant, and they do not support generalized wellness, aesthetic, or performance claims.

    —

    FAQ

    • Does this packet include human outcome data for a non-DAC CJC-1295 variant?
    • No. The human evidence provided pertains to a long-acting formulation; no direct human outcome data specific to a non-DAC variant are included.
    • What human findings are reported for CJC-1295 in this packet?
    • Prolonged GH and IGF-1 secretion in healthy adults and serum protein profile changes consistent with GH/IGF-1 axis activation—both biomarker-level findings, not demonstrated clinical outcomes [pubmed:16352683][pubmed:19386527].
    • Is there a disease-specific clinical trial?
    • A study in HIV-associated visceral obesity is registered, but this packet does not include peer-reviewed outcome data from that trial [clinicaltrials:NCT00267527].
    • Do the equine detection studies inform therapeutic effects in humans?
    • No. They describe analytical methods for detecting CJC-1295 or related analogs in equine plasma, not therapeutic outcomes [pubmed:30938069][pubmed:30489688].
    • Can biomarker changes be interpreted as proof of benefit?
    • No. Mechanistic/biomarker signals (e.g., GH/IGF-1 increases, serum protein shifts) do not establish clinical efficacy [pubmed:16352683][pubmed:19386527].

    —

    References

    • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/ [pubmed:16352683]
    • Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. https://pubmed.ncbi.nlm.nih.gov/26771670/ [pubmed:26771670]
    • A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. https://pubmed.ncbi.nlm.nih.gov/30938069/ [pubmed:30938069]
    • An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. https://pubmed.ncbi.nlm.nih.gov/30489688/ [pubmed:30489688]
    • Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/ [pubmed:19386527]
    • A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. https://clinicaltrials.gov/study/NCT00267527 [clinicaltrials:NCT00267527]
    • PubChem compound record: CJC 1295. https://pubchem.ncbi.nlm.nih.gov/compound/91971820 [pubchem:91971820]
    • Google Patents search for CJC-1295. https://patents.google.com/?q=CJC-1295 [patent_search:cjc-1295]

  • What Does the Published Research Say About TB-500?

    Research Context

    • Nomenclature and heterogeneity: TB-500 is a label used for thymosin beta-4 (Tβ4)–related peptides. Analytical work has identified an N-terminal acetylated 17–23 fragment of Tβ4 in some products marketed as TB-500, particularly in doping-control contexts; product composition may vary and these findings should not be presumed universal across all products [semantic:10.1002/dta.1402]. These analytical data inform detection/regulatory discussions, not demonstrated efficacy.
    • Evidence mix in the packet: The packet includes human-context evidence in a vascular injury/restenosis setting (pathway-focused, not TB-500 administration) [pubmed:39873228], alongside a scoping review preprint [crossref:10.20944/preprints202605.1124.v1] and multiple reviews and preclinical/mechanistic sources. Reviews frame biological plausibility and translational context but do not replace primary human outcome evidence [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:38994967].
    • Clarifying scope: Direct human evidence exists in the packet but is narrow and should remain tied to the specific population and endpoints studied; it does not constitute interventional efficacy data for marketed TB-500 products [pubmed:39873228; crossref:10.20944/preprints202605.1124.v1].
    • Measurement caveat: Quantifying circulating Tβ4 shows assay-related variability; biomarker claims should be made cautiously [pubmed:29502471].
    • Scope limit: Conclusions below are confined to the supplied sources. Dosing, standardized safety, long-term outcomes, and broad efficacy/generalizability are not established in this packet.

    Key Takeaway

    Published research on TB-500 centers on thymosin beta-4 biology, with narrow human-context evidence tied to vascular injury pathways and no identified interventional trials of TB-500.

    Direct Answer

    • TB-500 is best understood as a Tβ4-related product; some marketed materials have been analytically identified as an N-acetylated Tβ4 17–23 fragment, but composition can vary. Much of the literature addresses endogenous Tβ4 biology rather than specific TB-500 formulations [semantic:10.1002/dta.1402].
    • The packet contains narrow, context-specific human evidence related to a CCN5–Tβ4–CD9 axis in vascular injury/restenosis and endothelial repair; this should not be interpreted as interventional efficacy data for TB-500 and should remain anchored to the studied population and endpoints [pubmed:39873228].
    • Most cited sources are reviews or preclinical/mechanistic; they provide rationale and hypotheses but do not establish clinical utility for TB-500 [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:22074294].
    • No randomized or controlled interventional human trials of TB-500 are identified in the supplied packet.

    Human Evidence (from the packet)

    • Vascular injury/restenosis context: One PubMed source implicates a CCN5–Tβ4–CD9 axis in suppressing injury-induced vascular restenosis and facilitating endothelial repair. Any conclusions should remain tied to the specific population, endpoints, and biological context described. This source does not evaluate interventional TB-500 administration and does not establish interventional efficacy for TB-500 products [pubmed:39873228].
    • Scoping review preprint: A scoping review on Tβ4 and TB-500 is included as a preprint; treat it as contextual review (not peer-reviewed primary human interventional evidence). Regardless of any summarized observations, it does not substitute for controlled human trials [crossref:10.20944/preprints202605.1124.v1].

    Practical boundary: When referencing human outcomes, do not imply that TB-500 (as marketed) was tested in randomized or controlled interventional human trials based on these sources. Keep statements narrowly aligned to the specific human context in the packet [pubmed:39873228].

    Review Context (mechanisms and translational framing)

    • Orthopaedics and sports medicine overviews discuss therapeutic peptides and mechanistic rationales for tissue repair/rehabilitation but do not provide primary clinical outcome evidence for TB-500 [pubmed:41490200; pubmed:41476424].
    • Reviews on beta-thymosins outline biology, distribution, and functional considerations relevant to Tβ4, supplying background but not proving clinical efficacy for TB-500 [pubmed:17468232; pubmed:17495248; pubmed:38994967].
    • Structural and cardioprotection-focused reviews detail Tβ4 structures and potential roles, largely in nonclinical contexts; these are hypothesis-generating, not established human outcomes [pubmed:27450728; pubmed:27450736].
    • Biomarker methods highlight variability in circulating Tβ4 assays, cautioning against strong inferences without standardized techniques [pubmed:29502471].

    How to use these reviews: as mechanistic/translational context and hypothesis generation. They do not substitute for primary, controlled human outcomes.

    Preclinical, Analytical, and Mechanistic Findings

    • Regeneration/repair biology: Nonclinical literature describes Tβ4 as involved in cellular repair and regeneration; such findings are hypothesis-generating and not equivalent to human clinical outcomes [pubmed:22074294].
    • Molecular interactions and structure: Work on Tβ4 interactions and structures informs mechanism but does not provide clinical endpoints [pubmed:12852258; pubmed:27450728].
    • Immune cell effects: Tβ4 and Tβ4-derived peptides can induce mast cell exocytosis in experimental systems; this is mechanistic, nonclinical evidence and not a demonstrated human outcome [crossref:10.1016/j.peptides.2007.01.004].
    • Cardiovascular context: A review discusses potential cardioprotective roles of Tβ4; in the provided sources this remains preclinical/mechanistic [pubmed:27450736].
    • Analytical/forensic identification: An N-acetylated 17–23 Tβ4 fragment has been identified in some products suspected of TB-500 doping; this supports nomenclature/identity clarification but not efficacy or safety claims [semantic:10.1002/dta.1402].

    Boundary condition: Preclinical and analytical findings should not be reframed as demonstrated human benefit or safety.

    Gaps and Open Questions

    • Generalized clinical efficacy for TB-500 across indications is not established; do not extrapolate beyond the specific human context identified in the packet [pubmed:39873228].
    • No randomized or controlled interventional human trials of TB-500 are identified in the packet; most sources are reviews or preclinical.
    • Dosing, standardized safety profiles, and long-term outcomes for TB-500 in humans are not defined by the supplied evidence.
    • Biomarker interpretation is limited by assay variability for circulating Tβ4 [pubmed:29502471].
    • Registry entries and patent searches are not efficacy evidence and should not be used as such [pubchem:62707662; patent_search:tb-500-tb500-thymosin-beta-4-thymosin-4].

    FAQ

    • Is there direct human evidence related to TB-500/Tβ4 in this packet?
    • The packet indicates direct human evidence exists but is narrow and pathway-focused in a vascular injury/restenosis context; it does not show interventional efficacy for marketed TB-500 products [pubmed:39873228; crossref:10.20944/preprints202605.1124.v1].
    • Are there randomized or controlled interventional human trials of TB-500 in the supplied sources?
    • No. The packet does not identify any randomized or controlled interventional trials of TB-500.
    • What exactly is TB-500 in the literature?
    • It refers to Tβ4-related peptides; analytical work has identified an N-acetylated Tβ4 17–23 fragment in some products, and composition may vary across marketed materials [semantic:10.1002/dta.1402].
    • Can circulating Tβ4 be used as a reliable biomarker here?
    • Caution is warranted; methodological variability complicates quantification and interpretation of circulating Tβ4 [pubmed:29502471].
    • Do reviews establish clinical efficacy for TB-500?
    • No. Reviews provide mechanistic and translational context but do not substitute for primary human outcome evidence [pubmed:41490200; pubmed:41476424; pubmed:17468232; pubmed:17495248; pubmed:38994967].

    References

    • Human-context study (pathway/biological context; not TB-500 administration):
    • [pubmed:39873228]
    • Reviews/translational and methods context:
    • [pubmed:41490200], [pubmed:41476424], [pubmed:17468232], [pubmed:17495248], [pubmed:38994967], [pubmed:27450728], [pubmed:27450736], [pubmed:29502471], [crossref:10.20944/preprints202605.1124.v1]
    • Preclinical/mechanistic and analytical:
    • [pubmed:22074294], [pubmed:12852258], [crossref:10.1016/j.peptides.2007.01.004], [semantic:10.1002/dta.1402]
    • Identifiers/registries (not efficacy evidence):
    • [pubchem:62707662], [patent_search:tb-500-tb500-thymosin-beta-4-thymosin-4]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About 5-Amino-1MQ?

    What Does the Published Research Say About 5‑Amino‑1MQ?

    Research Context

    • Topic focus: 5‑Amino‑1‑methylquinolinium (5‑Amino‑1MQ) appears in this packet as a chemical entity with a registry listing and a patent‑search record. The PubChem entry is a registry record (not functional validation) [pubchem:950107]. The patent‑search record indicates filings that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold; patents are not clinical evidence [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
    • Evidence composition: human observational/biomarker studies related to NNMT in disease contexts, review literature on NNMT biology and translational interest, and preclinical reports on NNMT inhibition and structure–activity relationships (SAR) [pubmed:39067875; pubmed:37576910; pubmed:34029690; pubmed:33453420; pubmed:35756670; pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:37523719; pubmed:29320176; pubmed:36622754; pubmed:31589440].
    • Scope note: the packet does not include human interventional trials of 5‑Amino‑1MQ or other NNMT inhibitors. Where human data are present, they are disease‑specific, observational, and focus on NNMT rather than on 5‑Amino‑1MQ per se.

    Key Takeaway

    Published studies in this packet do not include human trials of 5‑Amino‑1MQ. Human data relate to NNMT as a disease‑associated biomarker (UBC, CKD), while NNMT inhibition evidence is limited to animal and cell models. Registry and patent listings do not establish clinical efficacy or safety.

    Direct Answer

    • No human clinical trials of 5‑Amino‑1MQ are reported in the supplied literature. Human findings address NNMT associations in specific diseases (urothelial bladder cancer; chronic kidney disease) and should not be generalized as therapeutic efficacy [pubmed:39067875; pubmed:37576910].
    • NNMT inhibition has been studied preclinically (animal and cell models) across cardiac, liver, kidney, and oncology‑relevant contexts; these are not established human outcomes [pubmed:40484359; pubmed:32389809; pubmed:41543936; pubmed:36622754].
    • The packet provides a chemical registry entry and patent‑search context for 5‑Amino‑1MQ but no human dosing, safety, or efficacy data [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    Human evidence (observational/associational; not interventional)

    • Urothelial bladder cancer (UBC): NNMT in cancer‑associated fibroblasts is linked to tumor progression and resistance to immunotherapy, with mechanistic work alongside analyses in human UBC cohorts [pubmed:39067875].
    • Chronic kidney disease (CKD): NNMT is reported as a predictive marker of tubular fibrosis in human CKD cohorts [pubmed:37576910].
    • Interpretation boundaries: These studies inform NNMT’s disease associations and potential biomarker roles. They do not establish therapeutic benefit of NNMT inhibition or of 5‑Amino‑1MQ in humans [pubmed:39067875; pubmed:37576910].

    Review context (mechanistic framing; not a substitute for outcomes)

    • Reviews summarize NNMT’s catalytic role (methylation of nicotinamide to 1‑methylnicotinamide), its intersections with cellular metabolism and epigenetic regulation, and its potential as a biomarker/target across diseases [pubmed:34029690; pubmed:33453420; pubmed:35756670]. Mechanistic plausibility does not establish clinical utility.

    Preclinical evidence and chemical tools (non‑human)

    • Liver/metabolism: ER stress–induced NNMT upregulation contributes to alcohol‑related fatty liver development in preclinical models [pubmed:32389809].
    • Cardiac (mouse): NNMT inhibition improved cardiac structure and function in a heart‑failure‑with‑preserved‑ejection‑fraction mouse model [pubmed:40484359].
    • Kidney (non‑human): NNMT inhibition counteracted tubular senescence and fibrosis in early‑stage CKD models [pubmed:41543936].
    • Oncology/mechanisms (preclinical systems): m6A RNA modifications regulated chemotherapy response via NNMT [pubmed:36622754].
    • Chemical probes/SAR: discovery and optimization of NNMT bisubstrate and high‑affinity inhibitors, including cell‑potent tools, define tractable scaffolds and structure–activity relationships; these published inhibitor series are distinct from 5‑Amino‑1MQ and should not be cross‑extrapolated [pubmed:29320176; pubmed:31589440; pubmed:37523719].
    • Translation note: Animal/cell findings and chemical‑tool potency are not evidence of human clinical benefit or safety [pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:29320176; pubmed:31589440; pubmed:37523719; pubmed:36622754].

    Chemical identity and patent context for 5‑Amino‑1MQ

    • Chemical registry: 5‑Amino‑1‑methylquinolinium is indexed in PubChem as a compound record; the listing itself does not validate function or therapeutic use [pubchem:950107].
    • Intellectual property: A patent‑search record lists filings/applications that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold. Such records signal research interest but do not substitute for peer‑reviewed human efficacy or safety data [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    Limitations and open questions from this packet

    • No human interventional data for 5‑Amino‑1MQ or any NNMT inhibitor are presented.
    • Human findings are disease‑specific observational/biomarker associations (UBC; CKD) and should not be extrapolated to other conditions without new data [pubmed:39067875; pubmed:37576910].
    • Dosing, safety, and generalized risk profiles in humans are not addressed by this packet.
    • A substantial share of the evidence is preclinical, limiting translational certainty.

    FAQ

    • Is 5‑Amino‑1MQ clinically studied in humans?
    • No human clinical trials of 5‑Amino‑1MQ are included in the supplied literature. The packet provides only a registry entry and a patent‑search record for this compound [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
    • What human evidence exists around NNMT?
    • Observational studies link NNMT to tumor progression and immunotherapy resistance in urothelial bladder cancer and identify NNMT as a predictive marker of tubular fibrosis in CKD; these are not intervention trials and do not demonstrate therapeutic benefit [pubmed:39067875; pubmed:37576910].
    • What do animal and cell studies suggest about NNMT inhibition?
    • NNMT inhibition improved cardiac structure/function in a mouse HFpEF model, mitigated tubular senescence/fibrosis in CKD models, and mechanistic work connected NNMT to chemotherapy response; these are preclinical findings [pubmed:40484359; pubmed:41543936; pubmed:36622754].
    • Are the published NNMT inhibitor chemotypes the same as 5‑Amino‑1MQ?
    • No. The SAR series (bisubstrate and related high‑affinity inhibitors) are distinct chemotypes and should not be directly cross‑extrapolated to 5‑Amino‑1MQ [pubmed:29320176; pubmed:31589440; pubmed:37523719].
    • Does a registry or patent entry validate 5‑Amino‑1MQ as a therapy?
    • No. A PubChem listing is a registry record, and patent filings reflect intellectual property activity; neither is evidence of clinical efficacy or safety [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    References

    • [pubmed:39067875] NAD(+) metabolism enzyme NNMT in cancer‑associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. https://pubmed.ncbi.nlm.nih.gov/39067875/
    • [pubmed:40484359] Nicotinamide‑N‑methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model. https://pubmed.ncbi.nlm.nih.gov/40484359/
    • [pubmed:41543936] NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/41543936/
    • [pubmed:34029690] Nicotinamide N‑methyl transferase (NNMT): An emerging therapeutic target. https://pubmed.ncbi.nlm.nih.gov/34029690/
    • [pubmed:33453420] Nicotinamide N‑methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. https://pubmed.ncbi.nlm.nih.gov/33453420/
    • [pubmed:37523719] Structure‑Activity Relationship Studies on Cell‑Potent Nicotinamide N‑Methyltransferase Bisubstrate Inhibitors. https://pubmed.ncbi.nlm.nih.gov/37523719/
    • [pubmed:35756670] Nicotinamide N‑Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy. https://pubmed.ncbi.nlm.nih.gov/35756670/
    • [pubmed:37576910] Nicotinamide N‑Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD. https://pubmed.ncbi.nlm.nih.gov/37576910/
    • [pubmed:29320176] Discovery of Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/29320176/
    • [pubmed:36622754] N6‑Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N‑methyltransferase. https://pubmed.ncbi.nlm.nih.gov/36622754/
    • [pubmed:31589440] High‑Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/31589440/
    • [pubchem:950107] PubChem compound record: 5‑Amino‑1‑methylquinolinium. https://pubchem.ncbi.nlm.nih.gov/compound/950107
    • [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor] Google Patents search for 5‑Amino‑1MQ 5‑amino‑1‑methylquinolinium NNMT inhibitor. https://patents.google.com/?q=5-Amino-1MQ+5-amino-1-methylquinolinium+NNMT+inhibitor

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Follistatin-344?

    Research Context

    Follistatin is a secreted protein that binds and neutralizes activins and related TGF-β family ligands. “Follistatin-344” (FST344) refers to a 344–amino-acid isoform; however, most sources in this packet discuss follistatin generally (and sometimes follistatin-like 3, FSTL3), not isoform-specific clinical outcomes for FST344 [pubmed:9785474; pubmed:15253386; pubmed:37739334]. The packet contains:

    • Human studies in disease-specific, non-interventional contexts (FLT3/ITD acute myeloid leukemia target/biomarker work; circulating hormone profiling in steatotic liver disease; serum follistatin levels in ovarian endometriosis) [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Multiple reviews on activin/follistatin biology, signaling, inflammation/immunity, and related systems [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885].
    • Preclinical/mechanistic reports (cancer cachexia pathway mapping; angiogenin-binding) [pubmed:39116208; pubmed:17991437].
    • A nonclinical PK/PD study of an engineered human follistatin variant (not FST344) [crossref:10.1124/jpet.112.0313hia].
    • Forensic/analytical detection of black-market FST344 [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    Isoform specificity clarification: the packet does not present isoform-specific clinical data for FST344; conclusions should not assume equivalence between total follistatin, FST344, and FSTL3.

    Key Takeaway

    The supplied literature offers disease-specific human biomarker/target findings for follistatin but no interventional trials of exogenous FST344. Mechanistic reviews and preclinical studies provide context only and do not establish efficacy, safety, or dosing.

    Direct Answer

    In this packet, direct human evidence related to follistatin is narrow and disease-specific, focusing on target/biomarker work in FLT3/ITD acute myeloid leukemia, circulating hormone measurements in biopsy-proven steatotic liver disease, and serum levels in ovarian endometriosis cohorts [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1]. None of the cited human studies involve interventional administration of exogenous FST344. Mechanistic reviews describe how follistatin modulates activin/TGF-β pathways, providing context but not clinical outcomes [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885]. Preclinical reports map disease-relevant pathways and protein–protein interactions, and analytical studies document detection of black-market FST344; these do not establish clinical efficacy, safety, or dosing for FST344 [pubmed:39116208; pubmed:17991437; crossref:10.1124/jpet.112.0313hia; pubmed:31758732]. Overall, any conclusions should remain anchored to the specific human populations and endpoints studied and should not be generalized.

    Human Evidence (Disease-Specific and Observational)

    • FLT3/ITD acute myeloid leukemia: A study identified follistatin as a potential therapeutic target and biomarker in FLT3/ITD AML [pubmed:32134197]. This work concerns endogenous target/biomarker identification and does not test exogenous FST344 in humans.
    • Steatotic liver disease and steatohepatitis: A multicenter observational study measured circulating hormones, including follistatin, in biopsy-proven steatotic liver disease and steatohepatitis, providing biomarker data within that specific population [pubmed:37757973]. No interventional FST344 administration was involved.
    • Ovarian endometriosis: An observational study reported high serum follistatin levels in women with ovarian endometriosis, consistent with a biomarker association rather than interventional evaluation of FST344 [crossref:10.1016/s1090-798x(10)79409-1].

    Review Context and Mechanistic Background (Not Human Outcomes)

    • Foundational biology and signaling: Reviews summarize follistatin’s binding to activins and other TGF-β family ligands and activin receptor signaling, framing potential mechanisms relevant to diverse tissues [pubmed:9785474; pubmed:15253386].
    • Vascular and metabolic context: Reviews discuss activin/follistatin in atherosclerosis and the roles of follistatin and FSTL3 in metabolic disorders [pubmed:10077456; pubmed:37739334].
    • Immune/reproductive and inflammatory context: Activins, follistatin, and immunoregulation in the epididymis, and broader roles in inflammation and immunity, are discussed in review literature [pubmed:31322318; pubmed:21353885].

    Important clarifications:

    • Isoform specificity: Most reviews address “follistatin” generally; they are not isoform-specific for FST344.
    • Distinct proteins: FSTL3 (follistatin-like 3) is mechanistically related but distinct; findings for FSTL3 are not interchangeable with those for follistatin/FST344, and differential actions between follistatin and FSTL3 have been reported [pubmed:37739334; pubmed:15451564].

    Preclinical and Analytical/Forensic Findings (Nonclinical)

    • Cachexia pathway mapping: A single-nucleus study delineated molecular pathways associated with cancer cachexia–related muscle atrophy; it did not test FST344 or establish direct follistatin effects in humans [pubmed:39116208].
    • Protein–protein interaction: Follistatin was identified as an angiogenin-binding protein, a mechanistic interaction observed outside of human outcome trials [pubmed:17991437].
    • Engineered variant PK/PD (not FST344): A pharmacokinetic/pharmacodynamic study characterized an engineered human follistatin variant in nonclinical settings; it is not FST344 and is not human interventional evidence [crossref:10.1124/jpet.112.0313hia].
    • Forensic detection: Analytical studies detected “black market” FST344 in market/seized samples, indicating detectability but not informing product quality, dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    What Is Not Established (Limits of This Packet)

    • No interventional human trials of exogenous FST344 are included in this packet.
    • No randomized clinical trial evidence demonstrates clinical benefit or a defined safety profile for FST344 in broad indications.
    • No dosing, delivery, or regimen guidance is supported by the supplied literature.
    • Preclinical and mechanistic plausibility do not constitute proof of human efficacy or safety.
    • Broad claims (e.g., generalized anti-aging or multi-organ benefits) are unsupported by this packet.
    • Findings for total follistatin or FSTL3 should not be assumed to apply to the specific FST344 isoform without direct evidence.
    • Forensic detection of black-market FST344 does not speak to quality control, safety, dosing, or real-world effectiveness.
    • Conclusions should remain anchored to the specific human populations and endpoints studied [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].

    FAQ

    • What is Follistatin-344 (FST344)?
    • FST344 refers to a 344–amino-acid isoform of the follistatin protein, which binds activins and related TGF-β ligands. Most literature in this packet addresses follistatin broadly rather than FST344-specific outcomes [pubmed:9785474; pubmed:15253386].
    • Are there human trials testing exogenous FST344?
    • No interventional human studies of exogenous FST344 are included in this packet.
    • What human evidence is available?
    • Observational, disease-specific studies report follistatin as a biomarker/target in FLT3/ITD AML, measure circulating follistatin in steatotic liver disease, and report higher serum levels in ovarian endometriosis; none test exogenous FST344 [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Can findings about FSTL3 be applied to FST344?
    • No. FSTL3 is distinct from follistatin and shows differential actions; its findings are not interchangeable with those for follistatin/FST344 [pubmed:15451564; pubmed:37739334].
    • Do black-market detection studies tell us anything about safety or dosing?
    • No. These analytical reports document detection of FST344 in samples but do not inform dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    References

    • [pubmed:32134197]
    • [pubmed:37757973]
    • [crossref:10.1016/s1090-798x(10)79409-1]
    • [pubmed:9785474]
    • [pubmed:10077456]
    • [pubmed:37739334]
    • [pubmed:15253386]
    • [pubmed:31322318]
    • [pubmed:21353885]
    • [pubmed:15451564]
    • [pubmed:39116208]
    • [pubmed:17991437]
    • [crossref:10.1124/jpet.112.0313hia]
    • [pubmed:31758732]
    • [crossref:10.1002/dta.2741]
    • [crossref:10.1002/dta.2882]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Glutathione?

    Research Context

    The packet is dominated by review articles and mechanistic or preclinical literature on glutathione (GSH), its enzymes, and related pathways. Human data are limited and largely observational, centered on biomarker associations rather than interventional outcomes. Generalized efficacy, dosing, or safety conclusions are not supported by the supplied sources.

    Direct Answer

    Published research in this packet primarily characterizes glutathione biology—enzymology, transport, and roles in redox-regulated processes such as ferroptosis and cancer-related pathways [pubmed:36771108, pubmed:10101214, pubmed:23036594, pubmed:30427707, pubmed:37868994, pubmed:39125992]. Human evidence is limited to observational biomarker findings (e.g., altered GSH-related measures in schizophrenia) and reviews that synthesize mixed evidence types for brain disorders/aging and hypertension [pubmed:31039654, pubmed:35011559, pubmed:27511994]. These sources do not demonstrate that modifying glutathione levels yields clinical benefit in humans. The packet does not justify dosing guidance, generalized safety claims, or broad anti-aging efficacy.

    Human Evidence (Observational)

    • A systematic review and meta-analysis reports differences in glutathione levels and enzyme activities in patients with schizophrenia, reflecting biomarker associations rather than outcomes from glutathione supplementation or targeted modulation [pubmed:31039654]. This is not evidence of supplementation efficacy.
    • Reviews addressing brain disorders and aging and glutathione-related antioxidant defenses in hypertension synthesize mixed evidence streams (in vitro, animal, and limited human correlational data) and should be treated as context rather than causal clinical proof [pubmed:35011559, pubmed:27511994].

    Mechanistic and Review Context

    • Enzymatic systems: Reviews catalogue glutathione-related enzymes and catalytic mechanisms, including glutathione S-transferases and broader GSH-dependent proteins [pubmed:10101214, pubmed:36771108, pubmed:23036594].
    • Cellular handling: Subcellular distribution and membrane transport of glutathione are reviewed, outlining compartmentalization and transport processes [pubmed:30427707].

    Disease-Mechanism Reviews (Not Clinical Trials)

    • Cancer and ferroptosis: Reviews detail glutathione-dependent pathways in cancer cells and the regulation of ferroptosis, integrating substantial cell and animal data [pubmed:39125992, pubmed:37868994]. These mechanistic links do not establish clinical efficacy.
    • Brain/aging and hypertension: Narrative syntheses connect glutathione homeostasis to neurological and cardiovascular contexts, but do not supply interventional human trial evidence [pubmed:35011559, pubmed:27511994].
    • Related antioxidant agents: Reviews on ergothioneine in skin and on silymarin/silibinin in neuropsychiatric contexts pertain to different compounds and should not be conflated with glutathione-specific evidence [pubmed:36838636, pubmed:37612866].

    Preclinical and Non-Human Evidence

    • Non-human toxicology: Glutathione-dependent responses to toxic metals/metalloids are reviewed in fish models [pubmed:23334549].
    • Many mechanistic reviews above integrate in vitro and animal studies [pubmed:37868994, pubmed:39125992]. These inform biology but do not constitute human efficacy data.

    What Is Not Established by This Packet

    • Generalized anti-aging or longevity claims [pubmed:35011559].
    • Clinical utility inferred solely from mechanistic plausibility (e.g., ferroptosis regulation, cancer cell pathways) [pubmed:37868994, pubmed:39125992].
    • Dosing recommendations, comprehensive safety profiles, or broad off-label extrapolations.
    • Evidence that glutathione supplementation or targeted modulation improves clinical outcomes in humans; current human data are observational (biomarkers) [pubmed:31039654].

    References

    • [pubmed:37868994] Mechanisms and regulations of ferroptosis. https://pubmed.ncbi.nlm.nih.gov/37868994/
    • [pubmed:36838636] Safe and Effective Antioxidant: The Biological Mechanism and Potential Pathways of Ergothioneine in the Skin. https://pubmed.ncbi.nlm.nih.gov/36838636/
    • [pubmed:36771108] Glutathione-Related Enzymes and Proteins: A Review. https://pubmed.ncbi.nlm.nih.gov/36771108/
    • [pubmed:10101214] Glutathione S-transferases–a review. https://pubmed.ncbi.nlm.nih.gov/10101214/
    • [pubmed:39125992] Glutathione-Dependent Pathways in Cancer Cells. https://pubmed.ncbi.nlm.nih.gov/39125992/
    • [pubmed:31039654] Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/31039654/
    • [pubmed:35011559] Glutathione in Brain Disorders and Aging. https://pubmed.ncbi.nlm.nih.gov/35011559/
    • [pubmed:23334549] Glutathione and its dependent enzymes’ modulatory responses to toxic metals and metalloids in fish–a review. https://pubmed.ncbi.nlm.nih.gov/23334549/
    • [pubmed:30427707] Glutathione: subcellular distribution and membrane transport (1). https://pubmed.ncbi.nlm.nih.gov/30427707/
    • [pubmed:37612866] The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/37612866/
    • [pubmed:27511994] Role of glutathione metabolism and glutathione-related antioxidant defense systems in hypertension. https://pubmed.ncbi.nlm.nih.gov/27511994/
    • [pubmed:23036594] Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. https://pubmed.ncbi.nlm.nih.gov/23036594/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides